D3 Technologies Ltd is now Renishaw Diagnostics Ltd

Glasgow, Scotland, 11th May 2010: D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Resonance Raman Scattering (SERRS) for molecular diagnostics and research applications, today announced that it has changed its name to Renishaw Diagnostics Ltd.

David A. Burns, CEO (pictured right), said “the change of name to Renishaw Diagnostics reflects the direct focus of the Company to become the premier provider of automated multiplex diagnostic and clinical research systems. These patented technology based systems will enable our customers to carry out fast, reliable and simplified disease detection leading to improved patient care. This move demonstrates the outstanding commitment and belief of our parent company in our people, our strategy and our science, and brings the power of the Renishaw global enterprise to enable us to accelerate our development of these ground breaking products.“

Multiplex diagnostic platform

Renishaw’s Chairman and Chief Executive, Sir David McMurtry (pictured right), added, “We are in the process of doubling the footprint at Renishaw Diagnostics’ facilities in Glasgow and the team are recruiting a world-class commercial organisation that will enable us to take our diagnostics products directly to market. Development progress with our multiplex diagnostic platform has demonstrated our unique position in sensitivity, accuracy and speed compared to existing disease testing methods and has impressed our clinical partners.“

About Renishaw Diagnostics

Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. The Company is a pioneer in trace level detection technologies based on the exploitation of SERRS. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.

The Company is based in Glasgow, Scotland, and further information is available at www.renishawdiagnostics.com